VIVO VENTURES VII, LLC → Ascendis Pharma A/S ASND

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 15/100

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Moderate short days-to-cover (4.2 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

3 transactions

2 buys · 1 sales · 0 awards/exercises

Issuer Cluster

8 13D/G filings on this issuer

7 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-10-15

DTC 4.15

3,132,475 shares short · -10.1% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $28.33M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-08-14	BIENAIME JEAN JACQUES	director	Buy	1,100	$245.85	$270K
2026-08-14	BIENAIME JEAN JACQUES	director	Buy	900	$246.91	$222K
2026-05-11	JENSEN FLEMMING STEEN	officer	Sale	19,460	$238.49	$4.64M

Other 13D/G Filings on Ascendis Pharma A/S

Filed	Form	Filer	Stake	Shares
2020-03-05	SC	ORBIMED ADVISORS LLC	—	—	view →
2019-08-14	SC	ORBIMED ADVISORS LLC	—	—	view →
2019-03-12	SC	ORBIMED ADVISORS LLC	—	—	view →
2019-02-12	SC	Sofinnova Venture Partners IX, L.P.	—	—	view →
2019-01-11	SC	Sofinnova Venture Partners IX, L.P.	—	—	view →
2018-02-14	SC	Sofinnova Capital V FCPR	—	—	view →
2018-01-29	SC	ORBIMED ADVISORS LLC	—	—	view →

Other Filings by VIVO VENTURES VII, LLC

Filed	Form	Issuer	Stake	Shares
2019-02-14	SC	Aclaris Therapeutics, Inc. ACRS	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →